Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
about
Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failureMeta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failureThe effect of vitamin d on aldosterone and health status in patients with heart failure.Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb.Angiotensin receptor blockers in heart failure.The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain.BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.Role of angiotensin II in the evolution of diastolic heart failure.Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.Valsartan in the treatment of heart attack survivorsPredominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis ratsThe role of angiotensin receptor blockers in reducing the risk of cardiovascular disease.Association between aldosterone synthase (CYP11B2) -344C/T polymorphism and atrial fibrillation among Han and Kazak residents of the Xinjiang region.Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).Inhibition of atherosclerosis by angiotensin II type 1 receptor antagonists.First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents.Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions.Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in HeEffects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure.Assessing right ventricular function in pulmonary hypertension patients and the correlation with the New York Heart Association (NYHA) classification.Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.Aldosterone promotes atrial fibrillation
P2860
Q22306537-20378DA4-0DEA-47DF-B22A-91C41E1419CBQ28748219-D5312B5C-DE87-4974-995A-D24CA1247375Q30413123-E22489D6-7BB5-48B6-867B-C2935910B4ECQ33568512-9CF28CDC-6108-4164-AB91-4546D0C5B84AQ35580150-0AF4CCC9-2E8E-4099-A181-3E7DF9BCD924Q35883217-9A25D50D-9419-4010-A024-937F4BB489F1Q35987052-0EBCB4C8-4D0E-4B89-9A0E-C127904426AAQ36332211-14D299B0-4CC5-490D-A12E-18F17905617CQ36480076-42FBD274-7C26-4A45-B25D-1A95B3CE2F03Q36744015-84F4A072-885A-46D7-8D2D-A435BB7AD4B1Q36853840-B806F085-4FDA-40E3-9EFB-4DA6E0DA7ADCQ38011656-25969878-C1EF-4D77-8F74-FE4384943D61Q40779577-03BED32B-EAE5-46E4-AED4-60F16153C02FQ41202631-B8A5AAF2-09E9-4025-BFF0-DE6CA8942BF0Q43101047-27558E4D-5B9C-4963-AFE3-58A61E20BA19Q44065629-0FA07C3B-DD20-4F6B-BD10-F2E6A50A0BE5Q45979858-58D4B533-F721-4543-9E72-B8F430B79AF5Q46636762-FA1DE2CC-ECCA-4298-83CD-796DE19AF7C9Q46777484-C0467F27-154C-4148-9460-020EB809CA22Q48678090-EFCA3A14-F7B0-41B6-978E-D1112D93D5E1Q49827424-19BE87B1-0876-4C5D-B045-BB14B7969FC2Q53566573-23C6914D-DDFA-419E-9BB1-112645395FBCQ57298791-A7F46120-65F1-4072-8DEB-BE2398DB3AB0
P2860
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Sustained reduction of aldoste ...... Valsartan Heart Failure Trial.
@en
Sustained reduction of aldoste ...... Valsartan Heart Failure Trial.
@nl
type
label
Sustained reduction of aldoste ...... Valsartan Heart Failure Trial.
@en
Sustained reduction of aldoste ...... Valsartan Heart Failure Trial.
@nl
prefLabel
Sustained reduction of aldoste ...... Valsartan Heart Failure Trial.
@en
Sustained reduction of aldoste ...... Valsartan Heart Failure Trial.
@nl
P2093
P1433
P1476
Sustained reduction of aldoste ...... Valsartan Heart Failure Trial.
@en
P2093
Inder S Anand
Jay N Cohn
Robert Glazer
Roberto Latini
Serge Masson
Valsartan Heart Failure Trial Investigators
Yann-Tong Chiang
P304
P356
10.1161/01.CIR.0000091234.45664.62
P407
P577
2003-08-25T00:00:00Z